Skip to main content
Erschienen in: International Ophthalmology 2/2018

18.04.2017 | Original Paper

Effect of intravitreal aflibercept (Eylea®) on retrobulbar hemodynamics in patients with neovascular age-related macular degeneration

verfasst von: Mustafa Gok, Hasan Burhanettin Kapti

Erschienen in: International Ophthalmology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the short-term effect of single intravitreal aflibercept injection on retrobulbar blood flow in patients with neovascular age-related macular degeneration (nAMD).

Methods

Twenty eyes of 20 patients with nAMD scheduled for single intravitreal aflibercept (Eylea®) injection and 20 fellow eyes (uninjected) were enrolled in this prospective interventional study. The hemodynamic parameters of the ophthalmic artery (OA), central retinal artery (CRA) and posterior ciliary artery (PCA) comprising peak systolic velocity (PSV), end-diastolic velocity (EDV), and resistive index (RI) were measured by using color Doppler ultrasonography (CDU) in both injected and uninjected fellow eyes at baseline and 1 week after the injection.

Results

The measured first-week values of PSV and EDV in the CRA, OA and PCA showed a statistically significant reduction when comparing baseline values in both injected and uninjected fellow eyes (p = 0.0001). Also, it was found a significant increase in the post-injection RI values of all the CRA, OA, PCA in injected eye and OA in the uninjected eye (p = 0.0001). There was any significant difference between pre- and post-injection RI values of the CRA and PCA in the fellow eyes (p = 0.137, p = 0.736, respectively).

Conclusion

Single intravitreal administration of aflibercept alters retrobulbar blood flow velocities (BFVs) in both injected and uninjected fellow eyes in the short-term period.
Literatur
1.
Zurück zum Zitat Pascolini D, Mariotti SP, Pokharel GP et al (2004) 2002 global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol 11(2):67–115CrossRefPubMed Pascolini D, Mariotti SP, Pokharel GP et al (2004) 2002 global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol 11(2):67–115CrossRefPubMed
2.
Zurück zum Zitat Congdon N, O’Colmain B, Klaver CC, Eye Diseases Prevalence Research Group et al (2004) Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122(4):477–485CrossRefPubMed Congdon N, O’Colmain B, Klaver CC, Eye Diseases Prevalence Research Group et al (2004) Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122(4):477–485CrossRefPubMed
3.
Zurück zum Zitat Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2(2):e106–e116CrossRefPubMed Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2(2):e106–e116CrossRefPubMed
4.
Zurück zum Zitat Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537–2548CrossRefPubMed Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537–2548CrossRefPubMed
5.
Zurück zum Zitat Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431CrossRefPubMed Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431CrossRefPubMed
6.
Zurück zum Zitat Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116(1):57–65CrossRefPubMed Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116(1):57–65CrossRefPubMed
7.
Zurück zum Zitat Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ, CATT Research Group (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897–1908CrossRefPubMed Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ, CATT Research Group (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897–1908CrossRefPubMed
8.
Zurück zum Zitat Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW (2012) Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 154(2):222–226CrossRefPubMed Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW (2012) Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 154(2):222–226CrossRefPubMed
10.
Zurück zum Zitat Bonnin P, Pournaras JA, Makowiecka K et al (2014) Ultrasound assessment of ocular vascular effects of repeated intravitreal injections of ranibizumab for wet age-related macular degeneration. Acta Ophthalmol 92(5):e382–e387CrossRefPubMed Bonnin P, Pournaras JA, Makowiecka K et al (2014) Ultrasound assessment of ocular vascular effects of repeated intravitreal injections of ranibizumab for wet age-related macular degeneration. Acta Ophthalmol 92(5):e382–e387CrossRefPubMed
11.
Zurück zum Zitat Mete A, Saygili O, Mete A, Bayram M, Bekir N (2010) Effects of intravitreal bevacizumab (Avastin) therapy on retrobulbar blood flow parameters in patients with neovascular age-related macular degeneration. J Clin Ultrasound 38(2):66–70CrossRefPubMed Mete A, Saygili O, Mete A, Bayram M, Bekir N (2010) Effects of intravitreal bevacizumab (Avastin) therapy on retrobulbar blood flow parameters in patients with neovascular age-related macular degeneration. J Clin Ultrasound 38(2):66–70CrossRefPubMed
12.
Zurück zum Zitat Yuksel K, Altinkaynak H, Kina A, Kara N, Yazici AT, Demirok A (2013) Can intravitreal ranibizumab alter retrobulbar circulation in eyes with age-related macular degeneration? J Ocul Pharmacol Ther 29(8):723–727CrossRefPubMed Yuksel K, Altinkaynak H, Kina A, Kara N, Yazici AT, Demirok A (2013) Can intravitreal ranibizumab alter retrobulbar circulation in eyes with age-related macular degeneration? J Ocul Pharmacol Ther 29(8):723–727CrossRefPubMed
13.
Zurück zum Zitat Hosseini H, Lotfi M, Esfahani MH et al (2012) Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration. Retina 32(5):967–971CrossRefPubMed Hosseini H, Lotfi M, Esfahani MH et al (2012) Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration. Retina 32(5):967–971CrossRefPubMed
14.
Zurück zum Zitat Toklu Y, Cakmak HB, Raza S, Anayol A, Asik E, Simşek S (2011) Short-term effects of intravitreal bevacizumab (Avastin®) on retrobulbar hemodynamics in patients with neovascular age-related macular degeneration. Acta Ophthalmol 89(1):e41–e45CrossRefPubMed Toklu Y, Cakmak HB, Raza S, Anayol A, Asik E, Simşek S (2011) Short-term effects of intravitreal bevacizumab (Avastin®) on retrobulbar hemodynamics in patients with neovascular age-related macular degeneration. Acta Ophthalmol 89(1):e41–e45CrossRefPubMed
15.
Zurück zum Zitat Bonnin P, Pournaras JA, Lazrak Z et al (2010) Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin ®) in neovascular age-related macular degeneration. Acta Ophthalmol 88(6):641–645CrossRefPubMed Bonnin P, Pournaras JA, Lazrak Z et al (2010) Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin ®) in neovascular age-related macular degeneration. Acta Ophthalmol 88(6):641–645CrossRefPubMed
16.
Zurück zum Zitat Williamson TH, Harris A (1996) Color Doppler ultrasound imaging of the eye and orbit. Surv Ophthalmol 40(4):255–267CrossRefPubMed Williamson TH, Harris A (1996) Color Doppler ultrasound imaging of the eye and orbit. Surv Ophthalmol 40(4):255–267CrossRefPubMed
17.
Zurück zum Zitat Lieb WE, Cohen SM, Merton DA, Shields JA, Mitchell DG, Goldberg BB (1991) Color Doppler imaging of the eye and orbit. Technique and normal vascular anatomy. Arch Ophthalmol 109(4):527–531CrossRefPubMed Lieb WE, Cohen SM, Merton DA, Shields JA, Mitchell DG, Goldberg BB (1991) Color Doppler imaging of the eye and orbit. Technique and normal vascular anatomy. Arch Ophthalmol 109(4):527–531CrossRefPubMed
18.
Zurück zum Zitat Guthoff RF, Berger RW, Winkler P, Helmke K, Chumbley LC (1991) Doppler ultrasonography of the ophthalmic and central retinal vessels. Arch Ophthalmol 109(4):532–536CrossRefPubMed Guthoff RF, Berger RW, Winkler P, Helmke K, Chumbley LC (1991) Doppler ultrasonography of the ophthalmic and central retinal vessels. Arch Ophthalmol 109(4):532–536CrossRefPubMed
19.
Zurück zum Zitat Papadopoulos N, Martin J, Ruan Q et al (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15(2):171–185CrossRefPubMedPubMedCentral Papadopoulos N, Martin J, Ruan Q et al (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15(2):171–185CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Krohne TU, Holz FG, Meyer CH (2014) Pharmacokinetics of intravitreally administered VEGF inhibitors. Ophthalmologe 111(2):113–120CrossRefPubMed Krohne TU, Holz FG, Meyer CH (2014) Pharmacokinetics of intravitreally administered VEGF inhibitors. Ophthalmologe 111(2):113–120CrossRefPubMed
21.
Zurück zum Zitat Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM (2009) Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 54(3):652–6588CrossRefPubMedPubMedCentral Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM (2009) Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 54(3):652–6588CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Mendrinos E, Mangioris G, Papadopoulou DN, Donati G, Pournaras CJ (2013) Long-term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration. Acta Ophthalmol 91(3):e184–e190CrossRefPubMed Mendrinos E, Mangioris G, Papadopoulou DN, Donati G, Pournaras CJ (2013) Long-term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration. Acta Ophthalmol 91(3):e184–e190CrossRefPubMed
23.
Zurück zum Zitat Sacu S, Pemp B, Weigert G, Matt G et al (2011) Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion. Invest Ophthalmol Vis Sci 52(6):3046–3050CrossRefPubMed Sacu S, Pemp B, Weigert G, Matt G et al (2011) Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion. Invest Ophthalmol Vis Sci 52(6):3046–3050CrossRefPubMed
24.
Zurück zum Zitat Takahashi H, Shibuya M (2005) The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109(3):227–241CrossRef Takahashi H, Shibuya M (2005) The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109(3):227–241CrossRef
25.
Zurück zum Zitat Peters S, Heiduschka P, Julien S, Tübingen Bevacizumab Study Group et al (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143(6):995–1002CrossRefPubMed Peters S, Heiduschka P, Julien S, Tübingen Bevacizumab Study Group et al (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143(6):995–1002CrossRefPubMed
26.
Zurück zum Zitat Robinson F, Riva CE, Grunwald JE, Petrig BL, Sinclair SH (1986) Retinal blood flow autoregulation in response to an acute increase in blood pressure. Invest Ophthalmol Vis Sci 27(5):722–726PubMed Robinson F, Riva CE, Grunwald JE, Petrig BL, Sinclair SH (1986) Retinal blood flow autoregulation in response to an acute increase in blood pressure. Invest Ophthalmol Vis Sci 27(5):722–726PubMed
27.
Zurück zum Zitat Lovasik JV, Kergoat H, Riva CE, Petrig BL, Geiser M (2003) Choroidal blood flow during exercise-induced changes in the ocular perfusion pressure. Invest Ophthalmol Vis Sci 44(5):2126–2132CrossRefPubMed Lovasik JV, Kergoat H, Riva CE, Petrig BL, Geiser M (2003) Choroidal blood flow during exercise-induced changes in the ocular perfusion pressure. Invest Ophthalmol Vis Sci 44(5):2126–2132CrossRefPubMed
28.
Zurück zum Zitat Zehetner C, Kralinger MT, Modi YS et al (2015) Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Acta Ophthalmol 93(2):e154–e159CrossRefPubMed Zehetner C, Kralinger MT, Modi YS et al (2015) Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Acta Ophthalmol 93(2):e154–e159CrossRefPubMed
29.
Zurück zum Zitat Wang X, Sawada T, Sawada O, Saishin Y, Liu P, Ohji M (2014) Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. Am J Ophthalmol 158(4):738–744CrossRefPubMed Wang X, Sawada T, Sawada O, Saishin Y, Liu P, Ohji M (2014) Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. Am J Ophthalmol 158(4):738–744CrossRefPubMed
30.
Zurück zum Zitat Yoshida I, Shiba T, Taniguchi H et al (2014) Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 252(9):1483–1489CrossRefPubMed Yoshida I, Shiba T, Taniguchi H et al (2014) Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 252(9):1483–1489CrossRefPubMed
31.
Zurück zum Zitat Avery RL, Castellarin AA, Steinle NC et al (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98(12):1636–1641CrossRefPubMedPubMedCentral Avery RL, Castellarin AA, Steinle NC et al (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98(12):1636–1641CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Tschulakow A, Christner S, Julien S, Ludinsky M, van der Giet M, Schraermeyer U (2014) Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys. PLoS ONE 9(11):e113701CrossRefPubMedPubMedCentral Tschulakow A, Christner S, Julien S, Ludinsky M, van der Giet M, Schraermeyer U (2014) Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys. PLoS ONE 9(11):e113701CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Julien S, Biesemeier A, Taubitz T, Schraermeyer U (2014) Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol 98(6):813–825CrossRefPubMed Julien S, Biesemeier A, Taubitz T, Schraermeyer U (2014) Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol 98(6):813–825CrossRefPubMed
34.
Zurück zum Zitat Harris A, Joos K, Kay M et al (1996) Acute IOP elevation with scleral suction: effects on retrobulbar haemodynamics. Br J Ophthalmol 80(12):1055–1059CrossRefPubMedPubMedCentral Harris A, Joos K, Kay M et al (1996) Acute IOP elevation with scleral suction: effects on retrobulbar haemodynamics. Br J Ophthalmol 80(12):1055–1059CrossRefPubMedPubMedCentral
Metadaten
Titel
Effect of intravitreal aflibercept (Eylea®) on retrobulbar hemodynamics in patients with neovascular age-related macular degeneration
verfasst von
Mustafa Gok
Hasan Burhanettin Kapti
Publikationsdatum
18.04.2017
Verlag
Springer Netherlands
Erschienen in
International Ophthalmology / Ausgabe 2/2018
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-017-0522-6

Weitere Artikel der Ausgabe 2/2018

International Ophthalmology 2/2018 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

CME: Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Wird ein Glaukom chirurgisch behandelt, ist die anschließende Wundheilung von entscheidender Bedeutung. In diesem CME-Kurs lernen Sie, welche Pathomechanismen der Vernarbung zugrunde liegen, wie perioperativ therapiert und Operationsversagen frühzeitig erkannt werden kann.

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.